Roche appointed Harmeier to return as head of its venture fund, reversing a prior leadership change and signaling renewed focus on external innovation sourcing. The BioCentury management brief notes Harmeier’s return and summarizes related executive moves at other biopharma companies. The leadership shift may affect Roche’s investment cadence and portfolio priorities, influencing deal flow for early‑stage biotech startups seeking strategic partnerships or venture backing from big pharma venture arms.